FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market
AstraZeneca $AZN has found a way to jump out in front of a pack of heavyweight PD-1/L1 rivals duking it out for a big piece of the blockbuster lung cancer market.
The day after Pfizer and Merck KGaA were forced to throw in the towel on a pivotal second-line lung cancer study for Bavencio, the FDA handed the UK pharma giant an approval to market Imfinzi to patients whose stage III non-small cell lung cancer hasn’t progressed after chemoradiation and whose tumors can’t be surgically removed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.